VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
Aiming to submit NDA in 2020-2021.
VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
Aiming to submit NDA in 2020-2021.
VTS-K: Ketamine + VTS Aspirin for Postoperative Pain
VTS-K: Ketamine + VTS Aspirin for Postoperative Pain
Aiming to Improve Patients' Lives in Multiple Sclerosis, Post-op Pain (Non-opioid), and Dyslipidemia
Vitalis is committed to improving the lives of patients
This mission provides the focus for everything we do, from early research to product development.
Our research is focused on changing the paradigm of patient treatment with efforts to discover innovative uses of existing medications.
Leveraging its VTS-Aspirin platform, Vitalis may help millions of patients each year, starting in three major treatment areas.